Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran – Authors' Reply Publisher Pubmed



Darvishian M1 ; Sharafkhah M2 ; Poustchi H2 ; Malekzadeh R3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Cancer Control Research, BC Cancer Research Centre, Vancouver, BC, Canada
  2. 2. Liver and Pancreatobiliary Research Center, Digestive Diseases Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, 14117–13135, Iran
  3. 3. Digestive Oncology Research Center, Digestive Diseases Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, 14117–13135, Iran
  4. 4. Digestive Disease Research Center, Digestive Diseases Research Institute, Shariati Hospital, Tehran University of Medical Sciences, Tehran, 14117–13135, Iran

Source: The Lancet Infectious Diseases Published:2021


Abstract

[No abstract available]
Related Docs
1. Estimates of Anti-Sars-Cov-2 Antibody Seroprevalence in Iran, The Lancet Infectious Diseases (2021)
Experts (# of related papers)